Schizophrenia (MIM181500) is a chronic, severe and disabling brain disorder that affects approximately 1% of the worldwide population and imposes an enormous burden on society 1,2 . It is a highly heritable psychiatric disorder (with an estimated heritability of 70-85% 3 ) with a substantial polygenic component including thousands of common alleles with small effects that contribute to disease risk 4 . Approximately 33-50% of the genetic risk of schizophrenia has been captured by common alleles in GWAS 5 . The evidence to date suggests that many risk alleles for common schizophrenia-associated genetic loci may be shared across ancestry groups, but others may be population specific because of differing causal variants or linkage disequilibrium (LD) patterns in populations of different ancestries 6 . Previous GWAS have identified more than 110 schizophreniaassociated loci and have substantially advanced understanding of this condition 5,7-13 . In particular, the most recent and largest schizophrenia GWAS (from the Schizophrenia Working group of the Psychiatric Genomics Consortium, PGC2) which, with discovery and extension, included a total of 36,989 schizophrenia cases and 113,075 controls, has identified 128 independent genome-wide significant associations spanning 108 loci 7 .
A r t i c l e s are essential for extending understanding of the genetic architecture of schizophrenia in the human population as a whole, for testing the generalizability of the results from European populations regarding this global disorder 6 and for identifying population-specific risk factors, should they exist.
To identify additional schizophrenia susceptibility loci and to gain a better understanding of the genes and biological pathways implicated in schizophrenia, we performed a GWAS including 7,699 cases and 18,327 controls of Chinese ancestry, as well as a transancestry GWAS meta-analysis with PGC2 (43,175 cases and 65,166 controls in total). The candidate loci found in each analysis were then studied in an independent replication sample of 4,384 schizophrenia cases and 5,770 controls of Chinese ancestry.
RESULTS

Results of GWAS screening in the Chinese population
We first conducted a GWAS for schizophrenia in the Chinese population (in comparison to the discovery phase of our prior GWAS report 10 , the number of cases was doubled, and the number of controls was tripled). After systematic quality control (QC) analysis and imputation to the 1000 Genomes Project data (Online Methods), we assessed the associations of 5,107,227 genetic variants in 7,699 schizophrenia cases and 18,327 controls (Supplementary Table 1 ). The primary GWAS comprised three samples that were genotyped on different platforms: 4,175 cases and 10,470 controls genotyped with the Affymetrix Genome-Wide Human SNP Array 6.0 (SNP6.0); 2,472 cases and 5,928 controls genotyped with the Affymetrix Axiom Genome-Wide CHB1 Array Plate (CHB1); and 1,052 cases and 1,929 controls genotyped with CHB1 or the Illumina 1M Array (1M). Principal component analysis (PCA) was used to assess population substructure ( Supplementary  Fig. 1 and Online Methods). For each subset, association testing was conducted with logistic regression including ancestry principal components (PCs) as covariates to adjust for population stratification. The results were combined with inverse-variance-weighted meta-analysis (based on a fixed-effects model). The genomic inflation factor (λ GC ) was 1.22, and the λ 1,000 (a scaled value to 1,000 cases and 1,000 controls) was 1.02. We conducted LD-score regression analysis 14 to distinguish the relative contributions of confounding bias and polygenicity. The LD-score regression intercept was 1.07 (s.e. = 0.01), and the slope was greater than zero, thus suggesting that most of the increase in the mean χ 2 statistic was from polygenic architecture rather than population stratification, in agreement with the previously documented polygenic nature of schizophrenia inheritance 7, 15 . However, given this modest elevation in the intercept, we further corrected the meta-analysis statistics for residual test-statistic inflation 14, 16 (Online Methods). Quantile-quantile and Manhattan plots are shown in Supplementary  Figures 2 and 3 . In this analysis ( Fig. 1) , we observed 66 GWS variants in a region previously reported to be associated with schizophrenia (2p16.1) 11, 12 .
The proportion of variance in susceptibility to schizophrenia explained by genome-wide SNP genotypes for individuals of Han Chinese ancestry (Online Methods) was estimated to be 31.5% (s.e. = 1.9%), assuming a population risk of 0.01. This result was similar to the corresponding estimate for European samples (33%) 5 , thus providing further evidence of the highly polygenic nature of schizophrenia beyond that in previous studies 7, 15 .
Results of the Chinese and PGC2 genome-wide meta-analysis
We performed a meta-analysis of the Chinese GWAS samples (7,699 schizophrenia cases and 18,327 controls) (denoted Chinese GWAS) and PGC2 GWAS samples (35,476 schizophrenia cases and 46,839 controls) to explore the effects of power and heterogeneity. A total of 4,303,606 genetic variants were common to the two data sets and were retained in the combined analysis. For combining the data, we used a fixed-effects model, but for variants with pronounced heterogeneity (I 2 >75%) 17 , we used a random-effects model to allow for the possibility that the presence of heterogeneity might result in test-statistic inflation. In our final result, the λ GC was 1.50, and the λ 1,000 was less than 1.01. The deviation of the observed statistics from the null hypothesis was less than that expected under a polygenic model for schizophrenia 7, 18 . Quantile-quantile and Manhattan plots are shown in Supplementary Figures 4 and 5. In the combined analysis, we detected 5,618 SNPs surpassing the threshold for GWS for association with schizophrenia. These SNPs mapped to 104 physically distinct associated regions, as defined by clumping the variants by using r 2 >0.1 and merging the LD-independent variants within 250 kb ( Fig. 1 and Supplementary Table 2) .
Results of the combined analysis with replication samples
We then obtained association results from an independent Chinese cohort of 4,384 schizophrenia cases and 5,770 controls 19 (Supplementary Table 1) for LD-independent SNPs with P <1 × 10 −5 in the Chinese-only GWAS meta-analysis or with P <5 × 10 −7 in the Chinese and PGC2 GWAS meta-analysis (Online Methods).
The combined analysis of the Chinese GWAS and replication samples resulted in a data set of 12,083 cases and 24,097 controls. Seven loci were GWS for association with schizophrenia in the meta-analysis of individuals of Chinese ancestry. Of those loci, three have been previously reported to be associated with schizophrenia ( Supplementary Fig. 6 ), and the other four are novel: rs2073499 at 3p21.31 (odds ratio (OR) = 0.899, fixed-effects meta-analysis P = 2.61 × 10 −8 ), rs7757969 at 6q21 (OR = 1.110, P = 4.82 × 10 −8 ), rs4479915 at 6q27 (OR = 0.876, P = 4.82 × 10 −9 ) and rs11534004 at 7q31.1 (OR = 0.890, P = 1.71 × 10 −8 ) (Fig. 2) . Four additional loci were significant at P <1 × 10 −5 in the Chinese GWAS meta-analysis and showed nominal evidence of replication (P <0.05) but were not GWS in the combined analysis. Results for all tested SNPs are presented in Supplementary Table 3 .
The combined results of the transancestry meta-analysis (43,175 schizophrenia cases and 65,166 controls) and replication samples (4,384 schizophrenia cases and 5,770 controls) identified a total of 109 GWS loci (Supplementary A r t i c l e s physically distinct loci: four loci were GWS only in the Chinese-only analysis, 106 were GWS only in the transancestry analysis, and three were present in both analyses (Supplementary Table 5 ). Of the 113 associated loci, 30 have not been previously reported ( Table 1) , four of which were GWS in the Chinese sample but not the transancestry analysis. In addition, at three of the previously reported loci, the GWS SNPs in the present study were in low LD with the previously identified GWS SNPs (r 2 <0.1 in both the European and Chinese populations), thus possibly suggesting independent signals in these regions (Supplementary Table 5 ).
Similarities and differences across ancestries
Of the 108 loci (128 index SNPs) identified in the PGC2 report 7 , we were able to investigate 103 loci (117 index SNPs or their proxies) that were in common between PGC2 and Chinese data sets (Supplementary Table 6 ). Of these, the PGC2-associated risk alleles were overrepresented in Chinese cases at 109 SNPs (from 98 loci), and at 58 SNPs (from 56 loci) this overrepresentation achieved nominal significance (P <0.05). In transancestry meta-analyses, 85 SNPs at 78 loci continued to be GWS. It is known that the random-effects model might be overly conservative 20 , and therefore on an exploratory basis, we performed a fixed-effects model meta-analysis for all these SNPs regardless of the existence of heterogeneity. Under the fixed-effects model, an additional eight SNPs (93 in total) at eight loci (86 loci in total) were GWS in the combined analysis. However, the results for the GWS SNPs indicated by fixed-effects meta-analysis and with evidence of heterogeneity should be interpreted with caution. Nevertheless, this finding suggested that the schizophrenia susceptibility loci identified in European samples were applicable to the Chinese sample. Moreover, the transancestry meta-analyses also confirmed two GWS loci (8p12 and 7q11.22) identified in our previous reports 10, 21 .
Regarding the seven GWS index SNPs analyzed in the Chineseonly analysis in this study, three replicated at P <0.05 in the PGC2 data set but showed significant heterogeneity (Higgins and Thompson I 2 index >75%) across populations and were not GWS in transancestry meta-analyses. In addition, one of the index SNPs (rs78681500) was absent in the PGC2 data set, owing to its rarity (minor allele frequency (MAF)<1%). Of the 117 GWS index SNPs identified in the transancestry analysis, all showed the same direction of effect across ancestries, and the I 2 was less than 75%.
We next assessed the genome-wide congruence of risk alleles across the PGC2 and Chinese GWAS data sets for LD-clumped independent SNPs 22 . For the schizophrenia-associated SNPs (P ≤0.0001) identified in the Chinese data set, we observed a highly significant excess of directional concordance in the PGC2 data set (67.7%, binomial test P = 3.06 × 10 −7 ). For the SNPs demonstrating weaker evidence of an association with schizophrenia (0.0001 < P ≤ 0.05), we also observed an excess of consistency in the direction of effect. In contrast, for the 
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SNPs with no evidence of association (P >0.5), there was no enrichment in coincident risk alleles across ancestry groups (Supplementary Table 7) . We repeated this analysis by identifying the schizophrenia risk alleles at SNPs in the PGC2 data set and assessing concordance in the direction of the effect in the Chinese data set, and we found a very similar pattern (Supplementary Table 7 ). We concluded that there was a significant excess in directional concordance across ancestry groups for the SNPs with evidence of a schizophrenia association.
Potential biological mechanisms of the associated loci
To determine the likely causal genes of the schizophrenia-associated genetic loci, we considered each of the following to represent evidence supporting a gene's causality within a locus (Online Methods): (i) being the gene nearest the index SNP 23 ; (ii) containing a missense mutation and being in high LD (r 2 >0.8) with the GWS SNPs 23 ; (iii) showing prioritization with DEPICT 24 ; (iv) being cis-acting expression quantitative trait loci (cis-eQTL) genes for the index SNPs 23,25-28 ; or (v) showing prioritization in summary-data-based Mendelian randomization (SMR) analysis 29 . Using these criteria, we prioritized 247 genes from the schizophrenia risk loci and found that 85 had more than one line of supporting evidence (defined as 'prioritized candidate genes') (Supplementary Table 8 ). We first focused on those genes in the newly identified loci ( Table 1) . As expected, some of those genes were plausibly biologically relevant. The index SNP rs2247870 (NP_115495.3, p.Val5876Ile) at 5q14.3 (GWS locus no. 37) is a missense variant in ADGRV1 (also known as GPR98), which encodes a member of the G-protein-coupled-receptor superfamily and is expressed in the central nervous system. Multiple lines of evidence suggest that G-protein-coupled receptors play critical roles in major psychiatric disorders (including schizophrenia) and their treatment 30 . A variant in GPR98 has been found to be associated with the response to antipsychotic treatment 31 . FYN (GWS locus no. 49) encodes a membrane-associated tyrosine kinase. FYN plays a critical role in neuronal apoptosis and is involved in brain development and synaptic transmission 32, 33 . Lower expression of FYN protein has been observed in the platelets of schizophrenic patients compared with controls 34 . The results from whole-blood eQTL analysis 27 indicated that the schizophrenia risk allele identified in this study (rs7757969[C]) was correlated with a lower expression of FYN (P = 1.71 × 10 −7 , with a false discovery rate <0.05 and in the credible interval covered by the 99% credible set), in agreement with previous findings. The estimate (b XY ) for the effect of gene expression on schizophrenia risk under the SMR analysis was −0.70 (P SMR = 7.55 × 10 −4 ). MAGI2 (GWS locus no. 54) encodes a synaptic scaffolding molecule that is essential for the development and maintenance of synapses 35 . Synaptic dysfunction has been suggested to play an important role in schizophrenia 36 . Common variants in MAGI2 have been found to be associated with cognitive impairment in people with schizophrenia 37 . Although it is currently difficult to pinpoint a causal gene that is responsible for a given locus, the prioritized genes may be considered as favorable candidates for further research to unravel the plausible biological mechanisms underlying the associations. 
A r t i c l e s
Improved fine-mapping resolution at the associated loci We sought to refine the localization of likely functional variants in the schizophrenia-associated loci by using a previously published approach 38, 39 . We derived Bayesian credibility sets in different data sets and evaluated the evidence for improved fine-mapping resolution through transancestry meta-analysis. For the 99% credible SNP sets, the transancestry data set produced the smallest spanned regions for ~80% (n = 88) of the tested loci (Supplementary Table 9 ), including 11 loci with a spanned region less than 30 kb. At 53 of the 88 loci, the number of genes that overlapped with the transancestry interval defined by a credible set was two or fewer. Of those overlapped genes mapping to the credible intervals in the 53 loci, 49.1% was were in the list of prioritized candidate genes, whereas the proportion was 12.4% and 5.1% for the analysis of PGC2 and Chinese data, respectively. We also conducted fine-mapping analysis with PAINTOR by leveraging the functional annotation data and LD information in multiancestry cohorts [40] [41] [42] . We integrated the primary functional categories (coding, UTR, promoter, DNase-hypersensitivity site, intronic and intergenic) proposed by Gusev et al. 41 . A total of 62 variants achieved a posterior probability of >0.80 in at least one of the single-population and transancestry analyses (Supplementary Table 10 ). Of them, 38 variants had a higher posterior probability in the transethnic analysis than in the single-population analyses, including an additional 16 variants that achieved a transancestry posterior probability of >0.80 but had a posterior probability <0.80 in the single-population analyses. Eleven (68.8%) of these 16 variants had at least one hit in the selected eQTL studies in HaploReg v4.1 (ref. 23 and Supplementary Table 11 ). For example, at GWS locus no. 80, rs12541 with a posterior probability of 0.926 (Supplementary Fig. 7a ) is in the UTR region of ESAM and correlated with its expression in whole blood (P = 3.62 × 10 −8 and in the 99% credible-set interval) 27 . A further example is GWS locus no. 103, rs3814883, which had a posterior probability of 0.911 ( Supplementary  Fig. 7b ) and is a synonymous variant of TAOK2 and also an eQTL SNP for several genes in different tissues 23 (Supplementary Table  12 ). It might also be correlated with the expression of SEZ6L2 in the brain cerebellum and frontal cortex (P = 2.37 × 10 −8 and 5.03 × 10 −8 , respectively) 26 . TAOK2 has been found to affect basaldendrite development in cortical neurons 43 . SEZ6L2 has been found to be a Cathepsin D transport receptor involved in neurite outgrowth 44 . To further explore the regulatory nature in the context of the cell-typespecific epigenome, we also integrated the reference epigenomes of seven highlighted marks for 127 human tissues and cell types produced by the Roadmap Epigenomics Project 45 (Online Methods). Of the top 100 enriched cell-type-specific epigenomic annotations for schizophrenia associations in the current and PGC2 analyses 7 , over 40 were related to the brain and nervous system (Supplementary Table 13 ). In the further PAINTOR fine-mapping analyses with the top 100 epigenomic annotations, many SNPs had higher posterior probabilities, some of which increased to a value >0.80, thus indicating potential biologically relevant cell types for these associations (Supplementary Table 14 ). For example, rs6670165, a candidate causal SNP at GWS locus no. 7, mapped to enhancers and promoters active in several brain regions. The identification of these SNPs suggested an important benefit of the transancestry fine-mapping signal in functional annotation data. However, 14 variants had a posterior probability >0.80 in the single-population analyses, which decreased to <0.8 in the transancestry analysis (Supplementary Table 10 ).
Biological pathways and gene sets
To identify pathways and gene sets in the transancestry meta-analysis, we performed an enrichment analysis with MAGMA 46 . We identified one gene set, 'regulation of insulin secretion by glucagon-like peptide 1' (from the Reactome database) that was significantly enriched (MAGMA competitive P = 5.14 × 10 −7 ; Fig. 3) . The MAGMA pathway analysis also highlighted several other pathways. Two of the previously highlighted schizophrenia-associated pathways, 'postsynaptic density' 47 and 'voltage-gated calcium channel complex' 7 , also ranked highly in our analysis, with P values of 9.01 × 10 −4 and 1.32 × 10 −3 , respectively (Supplementary Table 15 ).
Polygenic risk-score profiling
Polygenic scoring analyses have been proposed to predict the casecontrol status in a target data set, on the basis of the results from a training GWAS 4 . To assess the overlap between the common-variant signal in the European and Chinese populations and to provide estimates of the proportions of variance additionally explained by the Chinese sample, we conducted a polygenic scoring analysis. We randomly selected approximately 1,000 schizophrenia cases and 1,000 controls from the Chinese sample as the target sample and used four training data sets: (i) the PGC2 European-only data set (EUR49); (ii) the full PGC2 data set; (iii) the Chinese sample, excluding the target sample; and (iv) the Chinese plus PGC2 combined data set (Fig. 4) . The risk-profile SNPs (P thresholds (P T ) = 5 × 10 −8 , 1 × 10 −6 , 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5 and 1) from the European-only data set alone explained approximately 1.11% to 2.34% of the variance in the case-control status of the Chinese sample on the liability scale 48 (assuming a population risk of 0.01). When the Asian samples were included, the PGC2 data set explained approximately 1.52% to 3.51% of the variance. The Chinese data set alone explained approxi- A r t i c l e s mately 0.10% to 8.15% of the variance. In almost all situations, the combined data set (PGC2 plus Chinese) explained larger proportions of the variance (approximately 1.89% to 8.28%). For P T = 5 × 10 −8 , the proportion of the explained variance increased from 1.20% (EUR49), 1.52% (PGC2) and 0.10% (Chinese) to 1.89% (PGC2 plus Chinese); for P T = 0.05, it is increased from 2.34% (EUR49), 3.09% (PGC2) and 6.16% (Chinese) to 7.86% (PGC2 plus Chinese). To evaluate the increased variance explained by the newly identified GWS loci, we performed additional polygenic risk-score profiling trained on the full data set (GWAS excluding the target sample and with replication) and restricted to the newly identified loci with the Chinese sample included. These novel loci explained 1.34% of the variance, 30% of which was contributed by the loci from the Chinese-only analysis.
Correlations between two psychiatric disorders in the Chinese sample
Strong evidence of a shared genetic etiology between schizophrenia and other psychiatric disorders (such as bipolar disorder and major depressive disorder) has been observed in European samples 49, 50 . The degree of shared variation across psychiatric disorders in the Chinese population has been unclear. We estimated the genetic correlation between schizophrenia and major depressive disorder, two diseases for which Chinese GWAS data with large sample sizes are available, by using LD-score regression 14 . We observed a statistically significant genetic correlation between schizophrenia and major depressive disorder in the Chinese sample (r g = 0.43, s.e. = 0.08, LD-score regression P = 5.87 × 10 −8 ), in agreement with findings (r g = ~0.40) in the European samples 49 .
DISCUSSION
In the large GWAS analysis of schizophrenia in subjects of Chinese ancestry, we identified seven GWS loci, four of which were novel. In general, alleles identified as being associated at subthreshold levels of significance in the Chinese data set were also enriched in schizophrenia cases in the GWAS from PGC2, thus supporting the validity of combining the two data sets. The transancestry meta-analyses of the Chinese and PGC2 data identified 109 GWS risk loci, three of which were GWS in the Chinese-only analysis. Our analyses confirmed most of the previously identified schizophrenia loci and identified 30 novel loci.
We observed a significant excess in the directional consistency of schizophrenia risk alleles across ancestry groups, even at SNPs demonstrating only weak evidence of an association. These findings indicated that most schizophrenia risk loci were shared across these two ancestral populations, and transancestry meta-analysis provided a powerful means for identifying new loci and narrowing the association intervals. Polygenic scoring analysis also demonstrated notable increases in the explained variance in case-control status (PGC2-plus-Chinese training to Chinese target compared with PGC2 to Chinese target or Chinese training to Chinese target). However, this analysis also suggested that variants identified in European samples partially explained the genetic variance of schizophrenia in Chinese populations. Notably, estimates of the proportion of explained variance in liability were lower than those in European populations 7 , similarly to previous reports on transethnic analyses 4, 51 . Such lower estimates might be a result of differences in the allele frequencies and LD patterns between different populations 4 .
It has been suggested that there are also population-specific risk alleles for schizophrenia 6 and that, if so, cross-ancestry analyses might have less power than that of studies of individuals with a recent shared ancestry. We found that some GWS loci in the PGC2 report were not GWS in the PGC2-plus-Chinese combined analysis. Moreover, most of the GWS SNPs identified in the analysis of Chinese subjects showed strong heterogeneity only across ancestries, though three of them achieved nominal significance with the same sign in the PGC2 data set. Another SNP fell within the previous PGC2-identified locus, but it was rare (MAF <1%) in European populations. Thus, further transancestry fine-mapping, by leveraging the differences in the LD structure among diverse populations, may be an efficient approach to identify the causal variants underlying such associations and may also distinguish population-specific loci. Indeed, we also observed considerable improvements in the fine-mapping resolution at several susceptibility loci.
Our use of fine-mapping tools and functional annotations to analyze schizophrenia-associated loci identified numerous candidate genes with several lines of supporting evidence, including genes that have previously been implicated in schizophrenia (for example, FYN and MAGI2) and novel genes (for example, EMX1 and BNIP3L) within the novel loci. Moreover, pathway analyses highlighted several pathways that contribute to schizophrenia pathogenesis, including previously described pathways (the voltage-gated calcium-channel pathway and postsynaptic density) and a new pathway (regulation of insulin secretion by glucagon-like peptide 1). The latter has not been highlighted in previous genetic studies of schizophrenia, but evidence from other investigation types has linked insulin signaling to the pathophysiology of schizophrenia. Previous epidemiological data have suggested that individuals with schizophrenia, compared with the general population or healthy controls, have a higher prevalence of metabolic syndrome 52, 53 . Moreover, high prevalence rates of impaired glucose metabolism have been observed in drug-naive patients with schizophrenia 54 . A proteomic analysis has shown that levels of several proteins involved in energy metabolism are altered in the brains of schizophrenic people 55 . Our results provided further support for a role for insulin-related energy metabolism in the etiology of schizophrenia.
In summary, the Chinese (n = 36,180) and multiancestry (n = 118,495) GWAS meta-analysis and follow-up replication studies identified Figure 4 Polygenic risk-score profiling analysis. Polygenic risk-score profiling analysis using approximately 1,000 randomly selected schizophrenia cases and 1,000 controls from the Chinese sample as a target and deriving risk alleles from three training data sets: the PGC2 European-only (EUR49) data set (light blue); the full PGC2 data set (blue); the Chinese (Chn) sample excluding the target sample (light red); and the Chinese and PGC2 data sets combined (red). The x axis shows ten P-value thresholds (P T = 5 × 10 −8 , 1 × 10 −6 , 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5 and 1). The y axis is the estimate of the proportion of variance explained on the liability scale, which is converted from Nagelkerke's pseudo R 2 (computed by comparison of a full model including covariates and polygenic risk scores to a reduced model including covariates only).
ONLINE METhODS
Recruitment of research subjects. As in our previous study 10 , all cases of Chinese ancestry were inpatients or outpatients with a history of more than 2 years of schizophrenia, who were recruited from mental-health centers in China, interviewed by two independent psychiatrists and diagnosed according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria. All cases met the following two criteria: preoccupation with one or more delusions and frequent auditory hallucinations. However, none of the following symptoms were prominent: disorganized speech, disorganized or catatonic behavior, or flat or inappropriate effects. The controls were randomly selected from Chinese volunteers (from hospitals and a community survey) who were asked to reply to a written invitation to evaluate their medical histories. Lists of potential control subjects were screened for suitability as volunteers by excluding subjects with major mental illnesses. All participants provided written informed consent. The study was approved by the Ethics Committee of Human Genetic Resources at the Bio-X Institutes of Shanghai Jiao Tong University, in accordance with the tenets of the Declaration of Helsinki. We confirm that our study is compliant with the Guidance of the Ministry of Science and Technology (MOST) for the Review and Approval of Human Genetic Resources.
Genotyping, quality control and genotype imputation of the Chinese GWAS data. Several different genome-wide genotyping platforms were used in this study: Affymetrix Genome-Wide Human SNP Array 6.0 (SNP6.0), Affymetrix Axiom Genome-Wide CHB1 Array Plate and Illumina 1M Array.
For the SNP6.0 chips, the genotype calls were generated together by using Affymetrix Axiom Analysis according to the Best Practices Workflow for SNP6.0. Sample QC filtering of the GWAS data was first performed by excluding arrays with Contrast QC measurements (a metric developed by Affymetrix for SNP6.0 QC, n = 197) that were <0.4.
Step 1 genotyping was run on all CEL files passing QC over a subset of 20,000 SNPs, and samples with a call rate ≤97% were excluded (n = 285). The remaining samples were used for step 2 genotyping analysis. SNP polisher was then used for SNP QC, and the SNPs in the recommended categories (PolyHighRes, MonoHighRes, NoMinorHom and Hemizygous) were retained. Sex was established via genotyping and evaluated for each of the subjects, and samples with inconsistent sex (compared with the sample record) were removed (n = 79). Heterozygosity rates were calculated with the intent of removing deviations that exceeded 6 s.d. from the mean (n = 0). PLINK's identity-by-descent analysis was used to detect cryptic relatedness 56 (URLs). When a pair of individuals had PI_ HAT >0.2, the member of the pair with the lower call rate was excluded from the analysis (n = 259). SNPs with call rates <97% (n = 28,040), MAF <1% (n = 185,439) or significant deviation from Hardy-Weinberg equilibrium (HWE) in controls (HWE P ≤ 1 × 10 −6 , n = 20,344) were excluded. We also excluded population outliers on the basis of PCA. After application of quality-control criteria, a set of 590,413 SNPs for 14,645 individuals was generated for genotype imputation.
For the CHB1 chips, the genotype calls were generated together according to the Axiom Genotyping Solution Data Analysis Guide. Briefly, arrays with dish QC (DQC), a single-sample metric developed by Affymetrix for Axiom QC) values <0.82 were first excluded (n = 181). Samples that surpassed the DQC values were used for genotype calling with a subset of probe sets. Samples with a call rate <97% or in a nonpassing plate (an average call rate of passing samples <98.5%) were also excluded (n = 276). The post-QC samples were then coclustered, and genotype calls were produced with the Axiom Genotyping Algorithm v1 (Axiom GT1). SNP QC was also executed with the SNP polisher procedure, and the SNPs in the recommended categories were retained. Verification procedures for sex, relatedness and PCA outliers were also conducted in sample QC as described above (n = 289). SNPs with call rates <97% (n = 56,735), MAF <1% (n = 206) or significant deviations from HWE in controls (HWE P ≤ 1 × 10 −6 , n = 18,849) were excluded. After application of QC criteria, a set of 555,058 SNPs for 9,580 individuals was generated for genotype imputation.
For Illumina 1M chips, SNP genotypes were generated from normalized bead intensity data with Genome Studio. Samples with a call rate <97% were excluded (n = 35). Regular sample QC procedures for parameters including sex, relatedness, heterozygosity rate and PCA outlier checking, were performed as described above (n = 231). SNPs with call rates <97% (n = 35,743), MAF <1% (n = 89,032) or HWE P ≤ 1 × 10 −6 (n = 954) were excluded. After application of QC criteria, a set of 716,466 SNPs for 1,823 individuals was generated for genotype imputation.
For each GWAS data set, the entire set was imputed together as follows: the genotypes were phased with SHAPEIT (URLs) 57, 58 for each chromosome, and imputation was performed for each 5-Mb chromosome interval with IMPUTE2 (URLs) 59 . The haplotypes derived from the 1000 Genomes Project Phase 1 (release v3, URLs) were used as reference data 60 . Because two genotyping platforms were used for GWAS set 3, we used two phased reference panels in this special case, as proposed by Howie et al. 59 . For each platform, the prephased data from the other platform were used as the second reference panel. The variants with INFO >0.8, MAF >0.01, a call rate ≥97% and HWE P ≥ 1 × 10 −6 in the controls were saved for further analysis. Those present in at least two data sets were saved for the meta-analysis. A set of 5,107,227 genetic variants for 7,699 cases and 18,327 controls remained in the final analysis.
PGC2 GWAS data set. The PGC2 GWAS data set 7 comprised 49 case-control samples (34,241 cases and 45,604 controls) and three family-based samples (1,235 parent-affected offspring trios). All of the samples were from subjects of European ancestry, excluding three case-control samples from subjects of East Asian ancestry (1,836 cases and 3,383 controls). The summary results for the PGC2 data set and European only data set (EUR49) were downloaded from the PGC website (URLs).
Replication data set. The replication sample consisted of 4,384 cases and 5,770 controls of Han Chinese ancestry. More details of the general characteristics and genotyping have been presented in our previous research 19 . For the Chinese-only analyses, the independent SNPs with P <1 × 10 −5 in the Chinese GWAS analysis of pre-or postcorrection with the inflation factor were selected. For the transancestry analysis, the independent SNPs with P <5 × 10 −7 in the Chinese (pre-or postcorrection) and PGC2 GWAS meta-analyses were selected. The precorrection data sets were used only for including more candidate SNPs for replication. All the association results in this article were based on the postcorrection data sets, wherein the global inflations were controlled. A total of 295 SNPs were analyzed in the Chinese replication analysis.
Power calculations. Power calculations were performed with the GAS Power Calculator 61 with a range of genotype relative risks and disease-allele frequencies, assuming a population prevalence of 0.01 and a significance level of 5 × 10 −8 . For the Chinese-only (n = 36,180) and transancestry (n = 118,495) analyses, we had adequate power (>80%) to detect variants with low risk-allele frequencies (RAFs) of 0.03 with genotypic relative risks of 1.318 and 1.161, respectively. This sample size in Chinese-only analyses was large enough to achieve adequate power for risk variants with genotypic relative risks of 1.150 and RAFs of 0.14 to 0.85, and the transancestry analyses achieved adequate power for risk variants with 1.075 and RAFs of 0.15 to 0.84.
Statistical methods and bioinformatics analysis. Population substructure was evaluated through a PCA with EIGENSTRAT software (URLs), on the basis of LD-pruned autosomal SNP genotypes 62, 63 . Two rounds PCA were performed. One round with samples from the HapMap Project phase 3 (HapMap3) was performed to identify admixed samples, and the other round was performed for each subset of cases and controls, wherein individual outliers (>6 s.d. from the mean on any one of the top ten PCs) were identified and removed for five iterations, and final PCs reflecting subtle ancestry information for each sample were generated for further correction. In the Chinese GWAS stage, the association was analyzed for subsets by using a logistic regression model involving covariates for PCs to adjust for possible population stratification. We evaluated the effects of the 20 PCs on genome-wide test statistics to determine the PC inclusion in the final association analysis for each data set. In the Chinese replication stage, the associations between SNPs and schizophrenia risk were evaluated on the basis of logistic regression with SNPTEST 64 . The Higgins and Thompson I 2 index was used for assessing heterogeneity across data sets 65 . Both fixed-effects-model and random-effects-model meta-analyses were used in this study. The variants with pronounced heterogeneity (I 2 >75%) were combined in a random-effects model in the transancestry meta-analysis 17 .
